Molnupiravir
We are a manufacturer based in China, specializing in high-quality Molnupiravir for industrial clients worldwide. Technical support and custom formulation available.
Category：Active Pharmaceutical Ingredients | Brand：MT
Tags：Molnupiravir
Introduction
English Synonyms ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate Catalog ID101595 CAS NO.2492423-29-5 Purity 95% MDL NumberMFCD32663515 EINEC Molecular FormulaC13H19N3O7 Molecular Weight329.31
MOLNUPIRAVIR: TECHNICAL DATA SHEET
| Category | Specifications |
|---|---|
| Generic Name | Molnupiravir |
| CAS No. | 2349386-89-4 |
| Molecular Formula | C₁₃H₁₉N₃O₇ |
| Molecular Weight | 329.3 g/mol |
| Appearance | White to off-white powder |
| Solubility | Sparingly soluble in water |
Key Properties
| Property | Performance Data |
|---|---|
| Mechanism of Action | RNA-dependent RNA polymerase inhibitor |
| Antiviral Spectrum | SARS-CoV-2 (COVID-19) |
| Bioavailability | ~30% (oral) |
| Half-life | 3.3 hours |
| Storage Conditions | 20-25°C (protected from moisture) |
Clinical Data
| Parameter | Details |
|---|---|
| Indication | Mild-to-moderate COVID-19 (high-risk adults) |
| Dosage | 800 mg every 12 hours (5 days) |
| Efficacy | 30% risk reduction in hospitalization |
| FDA Approval | EUA (Dec 2021) |
Safety & Compliance
| Aspect | Details |
|---|---|
| Pregnancy Category | Contraindicated (teratogenic risk) |
| Common Side Effects | Diarrhea, nausea |
| Drug Interactions | Limited data |
References:
- FDA EUA Fact Sheet (2022)
- NEJM 2021;385:509-520
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
Inquiry
We'll reply within 24 hours
